金城医药：终止与荷兰Giskit的意向性合作项目

Core Points - Jin Cheng Pharmaceutical (300233) announced on November 27 that it has been negotiating exclusive commercialization rights for ExEm Foam, a drug owned by Dutch company Giskit, which is used for evaluating tubal patency in women with infertility in China [1] - Both parties have agreed to continue exclusive negotiations to reach a cooperation agreement and have extended the negotiation period until November 15, 2024 [1] - Despite the intention to cooperate, the negotiation progress has not met expectations, and no substantial agreement has been reached on key issues, leading the company to decide to terminate the intended cooperation project [1]